{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:03:34Z","timestamp":1784952214603,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.diabres.2022.109870","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:16:53Z","timestamp":1649330213000},"page":"109870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Hepatitis C virus infection and diabetes: A complex bidirectional relationship"],"prefix":"10.1016","volume":"187","author":[{"given":"Stefano","family":"Ciardullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4902","key":"10.1016\/j.diabres.2022.109870_b0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"8062","key":"10.1016\/j.diabres.2022.109870_b0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(78)90131-9","article-title":"Transmissible agent in non-A, non-B hepatitis","volume":"311","author":"Alter","year":"1978","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2022.109870_b0015","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1128\/jvi.70.6.3363-3371.1996","article-title":"Identification of a highly conserved sequence element at the 3'terminus of hepatitis C virus genome RNA","volume":"70","author":"Kolykhalov","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.diabres.2022.109870_b0020","doi-asserted-by":"crossref","unstructured":"Baumert TF. The Nobel Prize in medicine 2020 for the discovery of hepatitis C virus: transforming hepatology. Elsevier; 2020. p. 1303-5.","DOI":"10.1016\/j.jhep.2020.10.017"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0030","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2022.109870_b0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejim.2018.02.015","article-title":"Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas","volume":"53","author":"Andriulli","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.diabres.2022.109870_b0040","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1016\/j.diabres.2022.109870_b0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0050","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.diabres.2022.109870_b0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J Clin Investig"},{"key":"10.1016\/j.diabres.2022.109870_b0060","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2022.109870_b0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0070","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.510310320","article-title":"Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation","volume":"31","author":"Perseghin","year":"2000","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.diabres.2022.109870_b0075","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.13337","article-title":"Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?","volume":"37","author":"Orsi","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.diabres.2022.109870_b0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11154-017-9440-1","article-title":"Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature","volume":"19","author":"Fabiani","year":"2018","journal-title":"Rev Endocr Metab Disorders"},{"key":"10.1016\/j.diabres.2022.109870_b0085","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.diabres.2022.109870_b0090","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/hep.22251","article-title":"Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus","volume":"47","author":"Veldt","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2022.109870_b0095","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2010.04.035","article-title":"Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis","volume":"53","author":"Nkontchou","year":"2010","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.diabres.2022.109870_b0100","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/JVI.01672-07","article-title":"Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt\/protein kinase B signaling pathway for insulin resistance","volume":"82","author":"Banerjee","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.diabres.2022.109870_b0105","first-page":"1384","article-title":"Impaired IRS-1\/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes","volume":"38","author":"Aytug","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.21703","article-title":"Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines","volume":"46","author":"Cua","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2022.109870_b0115","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/j.1572-0241.2003.08728.x","article-title":"Tumor necrosis factor\u2013\u03b1\u2013induced insulin resistance may mediate the hepatitis C virus\u2013diabetes association","volume":"98","author":"Knobler","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabres.2022.109870_b0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2362.32.s3.4.x","article-title":"Identifying the links between obesity, insulin resistance and \u03b2-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes","volume":"32","author":"Greenberg","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabres.2022.109870_b0125","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.3748\/wjg.v20.i23.7089","article-title":"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen","volume":"20","author":"Lonardo","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"issue":"2","key":"10.1016\/j.diabres.2022.109870_b0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2022.109870_b0135","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.diabres.2022.109870_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jcm11020379","article-title":"HCV Genotype Has No Influence on the Incidence of Diabetes\u2014EpiTer Multicentre Study","volume":"11","author":"Rajewski","year":"2022","journal-title":"Journal of Clinical Medicine."},{"key":"10.1016\/j.diabres.2022.109870_b0145","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2337\/dc05-2509","article-title":"Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study","volume":"29","author":"Lecube","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2022.109870_b0150","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.510280531","article-title":"Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues","volume":"28","author":"Laskus","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.diabres.2022.109870_b0155","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2337\/diacare.28.4.940","article-title":"Hepatitis C virus infection and human pancreatic \u03b2-cell dysfunction","volume":"28","author":"Masini","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109870_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-017-0905-3","article-title":"A preliminary analysis of hepatitis C virus in pancreatic islet cells","volume":"14","author":"Blackard","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.diabres.2022.109870_b0165","doi-asserted-by":"crossref","unstructured":"Chen J, Wang F, Zhou Y, Jiang J, Ksimu S, Zhang X, et al. Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38\u03b4 MAPK-dependent exocytosis in pancreatic \u03b2-cells. Clin Sci. 2020;134:529-42.","DOI":"10.1042\/CS20190900"},{"key":"10.1016\/j.diabres.2022.109870_b0170","doi-asserted-by":"crossref","unstructured":"Wang Q, Chen J, Wang Y, Han X, Chen X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One. 2012;7:e38522.","DOI":"10.1371\/journal.pone.0038522"},{"issue":"10","key":"10.1016\/j.diabres.2022.109870_b0175","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/liv.14556","article-title":"Mechanisms for increased risk of diabetes in chronic liver diseases","volume":"40","author":"Svegliati\u2010Baroni","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0180","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jhep.2016.07.005","article-title":"Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences","volume":"65","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"issue":"9539","key":"10.1016\/j.diabres.2022.109870_b0185","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","article-title":"Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study","volume":"368","author":"Amin","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0190","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro","year":"2014","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2022.109870_b0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.diabres.2022.109870_b0205","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","article-title":"Chronic HCV infection is a risk of atherosclerosis. role of HCV and HCV-related steatosis","volume":"221","author":"Adinolfi","year":"2012","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.diabres.2022.109870_b0210","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s10620-014-3222-3","article-title":"Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature","volume":"59","author":"Wong","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.diabres.2022.109870_b0215","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1253\/circj.CJ-08-0459","article-title":"Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system","volume":"72","author":"Alyan","year":"2008","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.diabres.2022.109870_b0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apt.12234","article-title":"Associations of chronic hepatitis C with metabolic and cardiac outcomes","volume":"37","author":"Younossi","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.diabres.2022.109870_b0225","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/STROKEAHA.110.598136","article-title":"Hepatitis C virus infection and increased risk of cerebrovascular disease","volume":"41","author":"Lee","year":"2010","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0230","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5604\/01.3001.0011.7382","article-title":"Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Fabrizi","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabres.2022.109870_b0235","doi-asserted-by":"crossref","unstructured":"Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22:462. e1-. e3.","DOI":"10.1016\/j.cmi.2015.12.030"},{"key":"10.1016\/j.diabres.2022.109870_b0240","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40121-017-0171-0","article-title":"Effect of hepatitis C treatment with ombitasvir\/paritaprevir\/R+ dasabuvir on renal, cardiovascular and metabolic extrahepatic manifestations: a post-hoc analysis of phase 3 clinical trials","volume":"6","author":"Mehta","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"12","key":"10.1016\/j.diabres.2022.109870_b0245","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/jmv.24897","article-title":"Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: single center experience","volume":"89","author":"Abdel Alem","year":"2017","journal-title":"J Med Virol"},{"key":"10.1016\/j.diabres.2022.109870_b0250","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","article-title":"Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4","volume":"41","author":"Dawood","year":"2017","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/gut.2010.236158","article-title":"Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3","volume":"61","author":"Thompson","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0260","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2022.109870_b0265","doi-asserted-by":"crossref","unstructured":"Butt AA, Yan P, Shuaib A, Abou-Samra A-B, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019;156:987-96. e8.","DOI":"10.1053\/j.gastro.2018.11.022"},{"issue":"12","key":"10.1016\/j.diabres.2022.109870_b0270","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2022.109870_b0275","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2022.109870_b0280","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00592-018-1257-1","article-title":"The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis","volume":"56","author":"Carnovale","year":"2019","journal-title":"Acta Diabetol"},{"issue":"9","key":"10.1016\/j.diabres.2022.109870_b0290","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/liv.14905","article-title":"Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus\/diabetic individuals with chronic hepatitis or with cirrhosis","volume":"41","author":"Cacciola","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.diabres.2022.109870_b0295","article-title":"Consensus report: definition and interpretation of remission in type 2 diabetes","volume":"39","author":"Riddle","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109870_b0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.diabres.2022.109870_b0305","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.numecd.2021.04.016","article-title":"Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes","volume":"31","author":"Sasso","year":"2021","journal-title":"Nutr, Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.diabres.2022.109870_b0310","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.109870_b0315","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2022.109870_b0320","article-title":"Diabetes influences liver stiffness in chronic hepatitis C patients with and without virological cure: a longitudinal study","volume":"76","author":"Pontual","year":"2021","journal-title":"Clinics"},{"key":"10.1016\/j.diabres.2022.109870_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-77416-0","article-title":"Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus","volume":"10","author":"Abdelwahab","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.diabres.2022.109870_b0330","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.diabres.2022.109870_b0335","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10254","key":"10.1016\/j.diabres.2022.109870_b0340","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"The Lancet"},{"issue":"10166","key":"10.1016\/j.diabres.2022.109870_b0345","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.diabres.2022.109870_b0350","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.109870_b0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109870_b0360","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High Prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109870_b0365","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J Hepatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722006830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722006830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:21:00Z","timestamp":1759173660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722006830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":73,"alternative-id":["S0168822722006830"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109870","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus infection and diabetes: A complex bidirectional relationship","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109870"}}